Summary of demographic and baseline# characteristics (all extension patients)
| Omalizumab | Placebo | |
| Subjects | 254 | 229 |
| Sex M:F n | 130:124 | 109:120 |
| Race caucasian:other n | 239:15 | 203:26 |
| Age yrs | 41 (12–76) | 40 (12–72) |
| Duration of asthma yrs | 21 (2–68) | 19 (1–63) |
| Smoking status n (%) | ||
| Nonsmoker | 197 (77.6) | 175 (76.4) |
| Exsmoker | 57 (22.4) | 54 (23.6) |
| Daily BDP dose µg | 766.1 (500–1600) | 777.3 (400–1800) |
| Serum total IgE IU·mL−1 | 220.2 (21–785) | 204.1 (25–814) |
| FEV1 % pred | 70.0 (32–112) | 70.4 (22–109) |
| FEV1 reversibility %¶ | 26.3 (10–86) | 25.7 (12–103) |
| Asthma severity+ n (%) | ||
| Moderate | 197 (77.6) | 176 (76.9) |
| Severe | 57 (22.4) | 53 (23.1) |
Data are presented as mean (range) unless otherwise stated
M: male
F: female
BDP: beclomethasone dipropionate
IgE: immunoglosni‐E
IU: International Units
FEV1: forced expiratory volume in one second
#: baseline of core study
¶: % increase is FEV1 from baseline within 30 min of taking 200 µg salbutamol
+: severe=baseline FEV1 ≤65% pred and a mean total symptom score of >4 out of 9 for the last 14 days of the run-in period